LBPS — 4d Pharma Share Price
Last Trade - 00:00- $195.85m
- $185.25m
- £0.53m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | 0.21 | 0.53 | n/a | 16.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.
Directors
- Axel Glasmacher NEC (58)
- Duncan Peyton (51)
- John Beck (60)
- Alexander Stevenson (50)
- Glenn Dourado
- Paul Maier (73)
- David Norwood NED (51)
- Edgardo Baracchini
- Sandy Macrae
- Katrin Rupalla
- Last Annual
- December 31st, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- January 10th, 2014
- Public Since
- February 18th, 2014
- No. of Employees
- 115
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 180,300,967
- Address
- 9 Bond Court, LEEDS, LS1 2JZ
- Web
- https://www.4dpharmaplc.com/
- Phone
- +44 1138950130
- Auditors
- RSM UK Audit LLP
Latest News for LBPS
Similar to LBPS
89BIO ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
ADAGIO THERAPEUTICS ORD
NASDAQ Global Market
FAQ
As of Today at 11:30 UTC, shares in 4d Pharma are trading at $8.56. This share price information is delayed by 15 minutes.
Shares in 4d Pharma last closed at $8.56 and the price had moved by over the past 365 days. In terms of relative price strength the 4d Pharma share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for 4d Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
4d Pharma does not currently pay a dividend.
4d Pharma does not currently pay a dividend.
4d Pharma does not currently pay a dividend.
To buy shares in 4d Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $8.56, shares in 4d Pharma had a market capitalisation of $195.85m.
Here are the trading details for 4d Pharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LBPS
Based on an overall assessment of its quality, value and momentum 4d Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 4d Pharma is $5.56. That is 35% below the last closing price of $8.56.
Analysts covering 4d Pharma currently have a consensus Earnings Per Share (EPS) forecast of -£0.14 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4d Pharma. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $8.56, shares in 4d Pharma were trading -22.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 4d Pharma.
4d Pharma's management team is headed by:
- Axel Glasmacher - NEC
- Duncan Peyton -
- John Beck -
- Alexander Stevenson -
- Glenn Dourado -
- Paul Maier -
- David Norwood - NED
- Edgardo Baracchini -
- Sandy Macrae -
- Katrin Rupalla -
We do not have data on 4d Pharma's shareholders